


Percentage of participants without a fall in anti-S RBD below 15 U/mL

Strata + Infliximab + Vedolizumab



Number at risk

Strata

Infliximab
Vedolizumab

	0	8	16	24	32
Infliximab	2999	2536	1065	44	5
Vedolizumab	1468	1209	515	30	1

Weeks from baseline